Stock News

Pura Vida Investments Cut Synergy Pharmaceuticals Del (Call) (SGYP) Holding; Blue Martini Software (BLUE) Sentiment Is 1.79

Pura Vida Investments Llc decreased Synergy Pharmaceuticals Del (Call) (SGYP) stake by 62.66% reported in 2017Q3 SEC filing. Pura Vida Investments Llc sold 167,800 shares as Synergy Pharmaceuticals Del (Call) (SGYP)’s stock declined 35.42%. The Pura Vida Investments Llc holds 100,000 shares with $5.00 million value, down from 267,800 last quarter. Synergy Pharmaceuticals Del (Call) now has $505.90M valuation. The stock decreased 2.80% or $0.059 during the last trading session, reaching $2.051. About 2.31M shares traded. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has risen 24.44% since February 16, 2017 and is uptrending. It has outperformed by 7.74% the S&P500.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. The company has market cap of $10.46 billion. The Company’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. It currently has negative earnings. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications.

Among 8 analysts covering Synergy Pharmaceuticals (NASDAQ:SGYP), 6 have Buy rating, 1 Sell and 1 Hold. Therefore 75% are positive. Synergy Pharmaceuticals had 40 analyst reports since August 25, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, June 12 by H.C. Wainwright. The firm has “Buy” rating by H.C. Wainwright given on Thursday, October 1. The firm earned “Buy” rating on Friday, September 8 by Cantor Fitzgerald. The stock of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) earned “Buy” rating by Rodman & Renshaw on Monday, March 21. On Thursday, February 1 the stock rating was maintained by H.C. Wainwright with “Buy”. H.C. Wainwright maintained Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) rating on Monday, December 4. H.C. Wainwright has “Buy” rating and $7.0 target. Cantor Fitzgerald maintained Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) on Thursday, November 9 with “Buy” rating. The stock of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has “Sell” rating given on Thursday, April 6 by Citigroup. Rodman & Renshaw maintained the stock with “Buy” rating in Friday, December 23 report. The company was reinitiated on Thursday, October 29 by Roth Capital.

Investors sentiment increased to 1.9 in Q3 2017. Its up 0.41, from 1.49 in 2017Q2. It improved, as 16 investors sold SGYP shares while 23 reduced holdings. 21 funds opened positions while 53 raised stakes. 147.06 million shares or 7.33% less from 158.68 million shares in 2017Q2 were reported. Ing Groep Nv has invested 0% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Goldman Sachs Gru accumulated 3.32 million shares or 0% of the stock. Parametric Associates Limited Co stated it has 0% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). 3,000 were accumulated by Equitec Specialists Ltd Liability Com. Geode Mgmt Limited Com holds 0% or 2.04M shares in its portfolio. California-based Malaga Cove Capital Limited Liability Co has invested 0.01% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Voya Investment Mngmt Limited Liability Corporation holds 0% or 104,372 shares. Ingalls Snyder Limited Co accumulated 10,000 shares. Truepoint Incorporated stated it has 29,000 shares. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 3,778 shares. Swiss Bank reported 0% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Northern Tru Corp holds 2.76 million shares or 0% of its portfolio. Hightower Advisors Ltd holds 845,264 shares. Pictet Asset Mngmt has 2.61M shares for 0.02% of their portfolio. Bancorporation Of America Corp De holds 0% or 88,245 shares.

Pura Vida Investments Llc increased Viewray Inc stake by 346,370 shares to 607,040 valued at $3.50B in 2017Q3. It also upped Sarepta Therapeutics Inc (NASDAQ:SRPT) stake by 20,000 shares and now owns 50,000 shares. Bio Rad Labs Inc (NYSE:BIO) was raised too.

Analysts await Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) to report earnings on March, 7. They expect $-0.20 EPS, up 35.48% or $0.11 from last year’s $-0.31 per share. After $-0.22 actual EPS reported by Synergy Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -9.09% EPS growth.

Cormorant Asset Management Llc holds 3.33% of its portfolio in bluebird bio, Inc. for 137,500 shares. Eventide Asset Management Llc owns 412,000 shares or 3.21% of their US portfolio. Moreover, First Light Asset Management Llc has 1.57% invested in the company for 36,085 shares. The Pennsylvania-based Emerald Advisers Inc Pa has invested 1.03% in the stock. Baillie Gifford & Co, a United Kingdom-based fund reported 5.32 million shares.

The stock increased 1.44% or $3 during the last trading session, reaching $211.65. About 416,252 shares traded. bluebird bio, Inc. (BLUE) has risen 112.34% since February 16, 2017 and is uptrending. It has outperformed by 95.64% the S&P500.

Leave a Reply

Your email address will not be published. Required fields are marked *